Lansforsakringar Fondforvaltning AB publ Sells 15,846 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Lansforsakringar Fondforvaltning AB reduced its stake in Edwards Lifesciences Corporation by 5.3%, selling 15,846 shares and holding a total of 280,871 shares worth approximately $20.36 million.
• Wall Street analysts have shown a favorable outlook for Edwards Lifesciences, with 15 analysts giving it a "Buy" rating, resulting in an average price target increase to $85.90.
• Edwards Lifesciences reported strong quarterly results, with $1.53 billion in revenue, beating estimates and showing an 11.9% growth compared to the previous year.

Lansforsakringar Fondforvaltning AB publ cut its holdings in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 5.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 280,871 shares of the medical research company's stock after selling 15,846 shares during the period. Lansforsakringar Fondforvaltning AB publ's holdings in Edwards Lifesciences were worth $20,358,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the business. Allspring Global Investments Holdings LLC raised its holdings in shares of Edwards Lifesciences by 0.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock valued at $2,170,000 after buying an additional 145 shares during the last quarter. Alyeska Investment Group L.P. acquired a new stake in shares of Edwards Lifesciences in the 4th quarter worth $49,038,000. Dynamic Advisor Solutions LLC boosted its holdings in shares of Edwards Lifesciences by 2.4% in the first quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company's stock valued at $1,124,000 after acquiring an additional 370 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in shares of Edwards Lifesciences by 13.5% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company's stock worth $5,582,000 after acquiring an additional 9,188 shares during the period. Finally, United Asset Strategies Inc. raised its holdings in Edwards Lifesciences by 10.4% during the first quarter. United Asset Strategies Inc. now owns 185,571 shares of the medical research company's stock worth $13,450,000 after purchasing an additional 17,412 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

EW has been the topic of a number of analyst reports. Argus raised Edwards Lifesciences to a "strong-buy" rating in a report on Thursday, July 10th. BTIG Research raised Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price objective on the stock in a report on Tuesday, July 29th. JPMorgan Chase & Co. raised their target price on Edwards Lifesciences from $80.00 to $85.00 and gave the company a "neutral" rating in a report on Friday, July 25th. Wells Fargo & Company upped their price target on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the stock an "overweight" rating in a research note on Thursday, August 7th. Finally, Truist Financial increased their price target on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the company a "hold" rating in a report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Edwards Lifesciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $85.90.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares of the company's stock, valued at $16,150,614. This trade represents a 4.15% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. This trade represents a 15.75% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 22,014 shares of company stock valued at $1,698,844 over the last 90 days. Corporate insiders own 0.34% of the company's stock.

Edwards Lifesciences Stock Down 0.9%

Edwards Lifesciences stock traded down $0.74 during midday trading on Wednesday, hitting $81.03. 668,370 shares of the company were exchanged, compared to its average volume of 4,465,081. The company's fifty day moving average price is $78.55 and its 200-day moving average price is $75.10. Edwards Lifesciences Corporation has a fifty-two week low of $64.00 and a fifty-two week high of $83.00. The company has a market cap of $47.57 billion, a PE ratio of 11.66, a price-to-earnings-growth ratio of 3.92 and a beta of 1.07. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same quarter in the previous year, the firm earned $0.70 earnings per share. The firm's revenue for the quarter was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.